<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03196297</url>
  </required_header>
  <id_info>
    <org_study_id>NN7415-4255</org_study_id>
    <secondary_id>U1111-1179-3872</secondary_id>
    <secondary_id>2016-000614-29</secondary_id>
    <secondary_id>JapicCTI-173682</secondary_id>
    <nct_id>NCT03196297</nct_id>
  </id_info>
  <brief_title>A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors</brief_title>
  <acronym>explorerâ„¢5</acronym>
  <official_title>A Multi-Centre Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Asia, Europe and the United States of America (USA). The aim of
      the trial is to assess the efficacy of concizumab administered s.c. (subcutaneously, under
      the skin) once daily in preventing bleeding episodes in patients with severe haemophilia A
      without inhibitors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 16, 2017</start_date>
  <completion_date type="Actual">June 3, 2020</completion_date>
  <primary_completion_date type="Actual">June 22, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of bleeding episodes</measure>
    <time_frame>During at least 24 weeks from treatment onset (week 0)</time_frame>
    <description>Count of episodes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of bleeding episodes</measure>
    <time_frame>During at least 76 weeks from treatment onset (week 0)</time_frame>
    <description>Count of episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of spontaneous bleeding episodes</measure>
    <time_frame>During at least 24 weeks from treatment onset (week 0)</time_frame>
    <description>Count of episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of spontaneous bleeding episodes</measure>
    <time_frame>During at least 76 weeks from treatment onset (week 0)</time_frame>
    <description>Count of episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>During at least 24 weeks from treatment onset (week 0)</time_frame>
    <description>Count of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of TEAEs</measure>
    <time_frame>During at least 76 weeks from treatment onset (week 0)</time_frame>
    <description>Count of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of anti-concizumab antibodies</measure>
    <time_frame>During at least 24 weeks from treatment onset (week 0)</time_frame>
    <description>Count of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of anti-concizumab antibodies</measure>
    <time_frame>During at least 76 weeks from treatment onset (week 0)</time_frame>
    <description>Count of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fibrinogen</measure>
    <time_frame>During 24 weeks from treatment onset (week 0)</time_frame>
    <description>Change in g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fibrinogen</measure>
    <time_frame>During at least 76 weeks from treatment onset (week 0)</time_frame>
    <description>Change in g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in D-dimer</measure>
    <time_frame>During 24 weeks from treatment onset (week 0)</time_frame>
    <description>Measured in ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in D-dimer</measure>
    <time_frame>During at least 76 weeks from treatment onset (week 0)</time_frame>
    <description>Measured in ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in prothrombin fragment F1 + 2 (F1 + 2)</measure>
    <time_frame>During 24 weeks from treatment onset (week 0)</time_frame>
    <description>Measured in pmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in F1 + 2</measure>
    <time_frame>During at least 76 weeks from treatment onset (week 0)</time_frame>
    <description>Measured in pmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in prothrombin time (PT)</measure>
    <time_frame>During 24 weeks from treatment onset (week 0)</time_frame>
    <description>Measured in seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PT</measure>
    <time_frame>During at least 76 weeks from treatment onset (week 0)</time_frame>
    <description>Measured in seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in activated partial thromboplastin time (APTT)</measure>
    <time_frame>During 24 weeks from treatment onset (week 0)</time_frame>
    <description>Measured in seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in APTT</measure>
    <time_frame>During at least 76 weeks from treatment onset (week 0)</time_frame>
    <description>Measured in seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in antithrombin (AT)</measure>
    <time_frame>During 24 weeks from treatment onset (week 0)</time_frame>
    <description>Measured in %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in AT</measure>
    <time_frame>After at least 76 weeks from treatment onset (week 0)</time_frame>
    <description>Measured in %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of concizumab</measure>
    <time_frame>Prior to the last dose administration at 24 weeks</time_frame>
    <description>Measured in ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of concizumab</measure>
    <time_frame>Prior to the last dose administration after at least 76 weeks</time_frame>
    <description>Measured in ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma free TFPI concentration value</measure>
    <time_frame>Prior to the last dose administration at 24 weeks</time_frame>
    <description>Measured in ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma free TFPI concentration value</measure>
    <time_frame>Prior to the last dose administration after at least 76 weeks</time_frame>
    <description>Measured in ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak thrombin generation</measure>
    <time_frame>Prior to the last dose administration at 24 weeks</time_frame>
    <description>Measured in nM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak thrombin generation</measure>
    <time_frame>Prior to the last dose administration after at least 76 weeks</time_frame>
    <description>Measured in nM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endogenous thrombin potential</measure>
    <time_frame>Prior to the last dose administration at 24 weeks</time_frame>
    <description>Measured in nM x min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endogenous thrombin potential</measure>
    <time_frame>Prior to the last dose administration after at least 76 weeks</time_frame>
    <description>Measured in nM x min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombin generation velocity index</measure>
    <time_frame>Prior to the last dose administration at 24 weeks</time_frame>
    <description>Measured in nM/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombin generation velocity index</measure>
    <time_frame>Prior to the last dose administration after at least 76 weeks</time_frame>
    <description>Measured in nM/min</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Haemostasis</condition>
  <condition>Haemophilia A</condition>
  <arm_group>
    <arm_group_label>Concizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily administration of concizumab to both on-demand and prophylaxis patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Concizumab</intervention_name>
    <description>0.15 mg/kg (with potential stepwise dose administration to 0.25 mg/kg) administered daily s.c (subcutaneously, under the skin). Treatment duration is 24 weeks in the main phase, and 52 weeks in the extension phase</description>
    <arm_group_label>Concizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Turoctocog alfa</intervention_name>
    <description>Breakthrough bleeding episodes will be treated by the patients at home with turoctocog alfa at the discretion of the study doctor, who will also choose dose levels</description>
    <arm_group_label>Concizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: - Informed consent obtained before any trial-related activities.
        Trial-related activities are any procedures that are carried out as part of the trial,
        including activities to determine the suitability for the trial - Male patients aged 18
        years or older at the time of signing informed consent, diagnosed with severe haemophilia A
        (FVIII activity below 1%), based on medical records or results at screening Exclusion
        Criteria: - Known or suspected hypersensitivity to trial product(s) or related products -
        Known inherited or acquired bleeding disorder other than haemophilia A - Presence of
        inhibitors (neutralising antibodies) to Factor VIII (equal to or above 0.6 Bethesda Units)
        at screening measured by the Nijmegen method
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Milano</city>
        <zip>20124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Aichi</city>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Nara</city>
        <zip>634-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>167-0035</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>MÃ¡laga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>MalmÃ¶</city>
        <zip>205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Solna</city>
        <zip>171 64</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bornova-IZMIR</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Edirne</city>
        <zip>22030</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ä°stanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Lviv</city>
        <zip>79044</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Belfast</city>
        <zip>BT9 7AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 20, 2017</study_first_submitted>
  <study_first_submitted_qc>June 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2017</study_first_posted>
  <disposition_first_submitted>September 4, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>September 4, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 11, 2019</disposition_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

